ImmunoCellular to add EphA2 antigen from Pitt to cancer vaccine cocktail
This article was originally published in Scrip
With a license from the University of Pittsburgh for the tyrosine kinase receptor, ImmunoCellular Therapeutics picked up one more antigen to mix in the cocktail it's formulating for a cancer vaccine.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.